The mission envisages Covid-19 vaccine development with end-to-end focus from preclinical through clinical development and manufacturing and regulatory facilitation, the DBT said.

Earlier this month, the government had announced a package of Rs 900 crore for vaccines.

Besides, Covaxin, four other vaccines are under different phases of clinical trial in India with the Serum Institute of India conducting phase-three trial of the Oxford-Astrazeneca Covid-19 vaccine while the indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country.